Loading...
XNAS
NDRA
Market cap2mUSD
Jun 16, Last price  
3.39USD
1D
-1.74%
1Q
-15.36%
IPO
-99.91%
Name

ENDRA Life Sciences Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-11.63%
Rev. gr., 5y
-70.98%
Revenues
0k
559,3551,410,064515,582351,6226,174000000
Net income
-12m
L+14.39%
-2,180,878-2,279,204-2,775,369-5,376,962-9,796,261-15,554,530-11,966,769-11,189,705-13,200,625-10,060,250-11,507,947
CFO
-7m
L-22.50%
-1,397,229-842,727-1,315,623-3,300,914-7,702,481-8,588,851-10,770,595-11,122,384-12,769,371-9,548,775-7,400,547
Earnings
Aug 20, 2025

Profile

ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
URL
https://www.endrainc.com/
IPO date
Jun 28, 2017
Employees
21
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
10,817
10,796
13,392
Unusual Expense (Income)
NOPBT
(10,817)
(10,796)
(13,392)
NOPBT Margin
Operating Taxes
22
Tax Rate
NOPAT
(10,817)
(10,796)
(13,413)
Net income
(11,508)
14.39%
(10,060)
-23.79%
(13,201)
17.97%
Dividends
(5)
(840)
(8)
Dividend yield
0.41%
0.00%
0.00%
Proceeds from repurchase of equity
1,148
6,483
8,400
BB yield
-90.77%
-0.68%
-1.43%
Debt
Debt current
97
202
181
Long-term debt
584
558
884
Deferred revenue
Other long-term liabilities
799
Net debt
(2,548)
(2,074)
(3,824)
Cash flow
Cash from operating activities
(7,401)
(9,549)
(12,769)
CAPEX
(16)
(34)
(203)
Cash from investing activities
(13)
(25)
(203)
Cash from financing activities
7,809
7,518
8,400
FCF
(10,999)
(8,406)
(14,274)
Balance
Cash
3,229
2,834
4,889
Long term investments
Excess cash
3,229
2,834
4,889
Stockholders' equity
(103,438)
(91,924)
(81,864)
Invested Capital
107,382
97,977
89,615
ROIC
ROCE
EV
Common stock shares outstanding
202
9,037
2,891
Price
6.26
-94.09%
106.00
-47.91%
203.50
-70.58%
Market cap
1,265
-99.87%
957,930
62.81%
588,378
-58.43%
EV
(1,283)
955,856
584,554
EBITDA
(10,611)
(10,521)
(13,158)
EV/EBITDA
0.12
Interest
22
Interest/NOPBT